Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of mepolizumab in the NHS in England.
NICE is unable to make a recommendation on the use of mepolizumab for the treatment of patients 6 years of age and older with eosinophilic granulomatosis with polyangiitis because GSK did not provide an evidence submission.
